Moderna stock, $MRNA , surges over +110% after announcing the first ever positive Phase 3 results for a personalized cancer vaccine.
Summary
Moderna and Merck announced positive Phase 3 results for their personalized cancer vaccine, which reduced melanoma recurrence, causing Moderna stock to surge by over 110%.
Similar Articles
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
Moderna and Merck announced the success of their mRNA cancer vaccine in a Phase 3 melanoma trial, which could establish a new personalized treatment paradigm for cancer.
Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma
Moderna and Merck announced positive Phase 3 results for intismeran autogene, an mRNA-based individualized neoantigen therapy, in adjuvant treatment for melanoma.
Moderna's Vaccine Breakthrough Supported by AI: Musk Praises mRNA Despite 'Obvious Misuse During COVID'
Moderna and Merck's Phase 3 trial of an mRNA cancer vaccine, personalized using AI algorithms, shows promising results for melanoma treatment, with Elon Musk praising mRNA's potential despite past controversies.
Moderna’s new cancer vaccine (mRNA-4157) is basically an AWS cloud pipeline that "compiles" a custom drug for your specific tumor.
Moderna and Merck's mRNA-4157 vaccine uses a cloud-based AI pipeline to create personalized cancer treatments, reducing recurrence risk by 49%. The FDA treats the AI software as part of the drug, marking a significant integration of technology in oncology.
@WSJ: An experimental cancer vaccine kept melanoma from coming back. It’s the first successful late-stage mRNA study validati…
An experimental mRNA-based cancer vaccine has successfully prevented melanoma from returning in a late-stage study, marking the first validation of decades of custom-treatment research.